Celecoxib-d3

• CAT Number: S000417
• CAS Number: 544686-18-2
• Molecular Formula: C17H11D3F3N3O2S
• Molecular Weight: 384.39
• Purity: ≥95%
• Target: COX
• IUPAC Name: 4-[5-[4-(trideuteriomethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
• InChI: InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)/i1D3
• InChIKey: RZEKVGVHFLEQIL-FIBGUPNXSA-N
• SMILES: CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

Celecoxib-d3（Cat No.:S000417） is a deuterated version of celecoxib, where three hydrogen atoms are replaced with deuterium. This modification is designed to enhance the drug’s metabolic stability, aiding in detailed pharmacokinetic studies. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) specifically classified as a COX-2 inhibitor, used primarily to relieve pain and inflammation in conditions like arthritis. It selectively inhibits the enzyme cyclooxygenase-2 (COX-2), which plays a key role in inflammation. The deuterated version, Celecoxib-d3, helps researchers understand how the drug is metabolized in the body, potentially leading to improved therapeutic efficacy and safety.